ClinicalTrials.gg
RecruitingNCT04353375Updated Dec 31, 2025

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

A Phase 2/3 interventional study of HMPL-453 in Advanced Intrahepatic Cholangiocarcinoma and Solid Tumor, Adult, sponsored by Hutchmed. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Hutchmed · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
235
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies in Cholangiocarcinoma with a site in China — 114 open to participants now, 125 under way, 12 of them phase 3. Cholangiocarcinoma · China.

Planned enrollment
18th of 191
235 · median 51
Started
2020
with 23 others
Phase 2/3
7 of 230
2 open now
Primary completion
2028-06
later than 96 of 124 live
Registered
64th of 230
by date

Among the 230 studies in Cholangiocarcinoma with a site in China, this one is the 18th largest by planned enrollment of the 191 interventional ones that give a count, is one of 24 that started in 2020, is one of 7 in phase 2/3, reaches primary completion later than 96 of the 124 other live ones, and was the 64th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

114 of the 230 studies in Cholangiocarcinoma with a site in China are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Cholangiocarcinoma with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement. The main questions it aims to answer are:

To evaluate the objective response rate (ORR) of HMPL-453 tartrate in the treatment of patients with advanced intrahepatic cholangiocarcinoma (ICC) habouring fibroblast growth factor receptor (FGFR) 2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance Participants will receive HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days [Days 1 to 14] followed by 7 days off [Day 15 to 21], 21 days as a treatment cycle.]

Read the detailed description

This is an open-label, single-arm, multicenter phase 2/3b clinical study to evaluate the efficacy and safety of HMPL-453 tartrate in the treatment of patients with advanced ICC habouring FGFR2 fusions/rearrangements/mutations. The study consists of the following 4 cohorts.

Cohort 1: Approximately 12 patients with locally advanced unresectable or metastatic ICC habouring FGFR2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance are planned to be enrolled in this cohort to receive HMPL-453 tartrate 150 mg administered orally once daily (QD) continuously in 21-day cycles.

Cohort 2: A total of approximately 113-116 patients are planned to be enrolled in this cohort, divided into safety run-in and extension phases. Approximately 6 to 9 patients with solid tumors who failed standard treatment or had intolerable toxicity will be enrolled into the first phase (safety run-in phase), to receive HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days [Day 1 to 14], followed by 7 days off [Day 15 to 21], 21 days as a treatment cycle). Dose limiting toxicities (DLT) observation period consists of 28 days, in which a cycle of treatment will be received. Patients will enter second stage of cohort 2 (extension phase) after completion of safety run-in assessments. Approximately 20 patients with locally advanced unresectable or metastatic ICC habouring FGFR2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance will receive HMPL-453 tartrate 300 mg QD orally administered (for 14 consecutive days [Day 1 to 14], followed by 7 days off [Day 15 to 21], 21 days as a treatment cycle). Based on the efficacy and safety data of the enrolled patients, and after reaching an agreement with China Center for Drug Evaluation on 17 Feb 2023, approximately 87 patients with locally advanced unresectable or metastatic ICC habouring FGFR2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance will be enrolled to support registration submission as the registration study stage of this study, receiving HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days [Days 1 to 14] followed by 7 days off [Day 15 to 21], 21 days as a treatment cycle.

Cohort 3 (Confirmatory Study Cohort): A total of approximately 87 patients with locally advanced unresectable or metastatic ICC harbouring FGFR2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance are planned to be enrolled in this cohort, as the confirmatory study phase of this study. Patients will receive HMPL-453 tartrate 300 mg QD for 14 days (Days 1 to 14), followed by 7 days off (Days 15 to 21), (21-day treatment cycles).

Cohort 4 (Exploratory Cohort): Approximately 10 to 20 treatment-naïve patients with locally advanced unresectable or metastatic ICC harbouring FGFR2 fusions/rearrangements/mutations are planned to be enrolled in this cohort. Patients will receive HMPL-453 tartrate 300 mg QD orally for 14 days (Days 1 to 14), followed by 7 days off (Days 15 to 21) (21-day treatment cycles).

03

Conditions studied

  • Advanced Intrahepatic Cholangiocarcinoma
  • Solid Tumor, Adult

Browse trials for

Keywords

  • FGFR2 funsion
  • HMPL-453
  • ICC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have fully understood the study and voluntarily signed the ICF;
  2. Age ≥ 18 years;
  3. a. or cytologically confirmed advanced treatment failure solid tumor with standard patients (applicable to cohorts2 stage I); b. histologically or cytologically confirmed histologically or cytologically confirmed locally advanced unresectable or ICC patients with FGFR2 fusions/rearrangements/mutation (applicable to Cohort 1, Cohort 2 Stage II, Cohort 3 and Cohort 4)
  4. a. The patients have received at least one prior systemic treatment regimen for advanced ICC and has intolerable PD or toxicity(Cohort1-3); b. Patients who have not received any prior systemic therapy for advanced ICC(Cohort4)
  5. according to v1.1;
  6. performance status of 0 or 1;
  7. ≥ 12 weeks;
  8. Female patients or male patients with partners of must take effective measures per the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients who previously received selective FGFR targeting therapy;
  2. Received approved or researched systemic anti-tumor treatment within 3 weeks prior to the start of the study treatment;
  3. Radical radiotherapy within 4 weeks;
  4. Have received local anti-tumor treatment within 4 weeks;
  5. Major surgery requiring hospitalization or incomplete healing of the surgery incision within 4 weeks;
  6. Current or prior history of retinal detachment;
  7. Using a strong inducer or inhibitor of cytochrome P450 3A () within 2 weeks or 5 half-lives of the study treatment;
  8. Taking drugs or dietary supplementsthat may cause blood phosphorus and/or blood calcium to rise within 2 weeks prior to the start of the study treatment;
  9. above 1.5 or partial activated prothrombin time above 1.5 times ;
  10. History of active hepatopathy, including active viral hepatitis, or other active hepatitis, clinically significant moderate to severe liver cirrhosis;
  11. The patients with (HIV) infection;
  12. Active infection requiring systemic treatment within 1 week prior to the start of the study treatment;
  13. Screening blood phosphorus levels above ULN, or history of abnormal calcium phosphorus metabolism requiring clinical intervention or relevant medical history;
  14. Currently keratopathy confirmed by ophthalmological examination;
  15. Prior history of retinal detachment, or current diseases that may cause retinal detachment;
  16. Clinically significant arrhythmia or conduction abnormalities requiring clinical intervention;
  17. Patients with known deep venous thrombosis, treated with low molecular weight heparin (LMWH) or drugs with similar efficacy, and the investigator judges that the thrombosis is stable for ≥ 2 weeks ;
  18. Toxicities caused by prior anti-tumor treatment have not recovered to grade 0 or 1;
  19. The patient has any current disease or condition that affects drug absorption, or the patient cannot be orally administered;
  20. Combined with other malignant tumor or a history of other malignant tumor within 5 years prior to study screening;
  21. Patients currently has central nervous system , meningeal metastases or spinal cord compression, except in individual cases;
  22. Any other medical condition or clinically significant laboratory abnormalities judged by the investigator would make the patients unsuitable to participate in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
235 participants (estimated)

Study arms

  • Experimental
    HMPL-453

    HMPL-453 150mg QD HMPL-453 300mg QD

    Drug: HMPL-453

Interventions

  • Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2, Cohort\_3 and Cohort\_4:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Proportion of patients whose best overall response are confirmed CR or PR

    Time frame: Measured up to 6 months after the last patient has been enrolled or all patients have finished their last PFS follow up, whichever comes first

Secondary outcomes

  1. Disease control rate (DCR)

    Proportion of patients whose best overall response after treatment is confirmed CR or PR, or judged as SD (SD≥6 weeks)

    Time frame: Measured up to 6 months after the last patient has been enrolled or all patients have finished their last PFS follow up, whichever comes first

  2. Time to response (TTR)

    The time from the first dose of study drug to the first CR or PR in patients whose best overall response is a confirmed CR or PR

    Time frame: Measured up to 6 months after the last patient has been enrolled or all patients have finished their last PFS follow up, whichever comes first

  3. Duration of response (DoR)

    The time from initial CR or PR to PD or death from any cause, whichever comes first, in patients whose best overall response is a confirmed CR or PR

    Time frame: Measured up to 6 months after the last patient has been enrolled or all patients have finished their last PFS follow up, whichever comes first

  4. Progression-Free Survival (PFS)

    The time from the first study treatment to the onset of PD or death from any cause

    Time frame: Measured up to 6 months after the last patient has been enrolled or all patients have finished their last PFS follow up, whichever comes first

  5. Overall survival (OS)

    The time from the patients receiving the first study drug until the death due to any cause

    Time frame: up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jun 2028, 93 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2020
First posted
Apr 20, 2020
StartActual
Sep 3, 2020
Primary completionEst.
Jun 30, 2028
CompletionEst.
Feb 28, 2030
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04353375
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Apr 20, 2020
Start date
Sep 3, 2020
Primary completion
Jun 30, 2028 (estimated)
Completion
Feb 28, 2030 (estimated)
Last update
Dec 31, 2025

Study contacts

Bo Zhang
Contact
boz@hutch-med.com
+86 21 2067 1819
Jianming Xu, PhD
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fanregratinib

Start the discussion